Effectiveness of First-line Natalizumab Treatment in Patients with Highly Active Relapsing-remitting Multiple Sclerosis

Kim, Su-Hyun; Kim, Ho Jin

J Mult Scler > Volume 9(2); 2018 > Article

Case Report

Journal of Multiple Sclerosis 2018;9(2):21-23.
Published online September 1, 2018.

질환 활성도가 높은 다발성경화증 환자에서 나탈리주맙 일차 치료의 효과

김수현, 김호진

국립암센터 신경과

Effectiveness of First-line Natalizumab Treatment in Patients with Highly Active Relapsing-remitting Multiple Sclerosis

Su-Hyun Kim, Ho Jin Kim

Department of Neurology, Research Institute and Hospital of National Cancer Center, Goyang, Korea

Abstract

"Patients with highly active relapsing-remitting multiple sclerosis (RRMS) may benefit from early aggressive therapy instead of the escalation approach. Here we describe the outcome of a patient withhighly active RRMS (two relapses in the year after onset and a few gadolinium-enhancing lesions onbrain MRI) treated with natalizumab as a first-line treatment. Over 2 years of natalizumab treatment,no evidence of disease activity was observed. An early aggressive approach may improve treatmentoutcome in patients with highly active RRMS. Journal of Multiple Sclerosis 9(2):21-23, 2018"

Key Words: Multiple sclerosis, Natalizumab